Company news
Ernexa Therapeutics Inc. news in 2023
Ernexa Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
December 19, 2023
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
December 13, 2023
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
October 31, 2023
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
September 5, 2023
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
September 4, 2023
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
July 17, 2023
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
July 10, 2023
Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel
May 23, 2023
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
May 1, 2023
Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million
April 10, 2023
Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board
March 27, 2023
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
March 19, 2023
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
February 21, 2023
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
January 3, 2023
Decks in 2023
- Eterna Therapeutics — Investor Presentation (August 2023)
Investor deck · 18 slides · Aug 2, 2023